Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Neuro-Oncology Practice|January 8, 2025
Financial challenges of being on long-term, high-cost medicationsCleopatra Elshiekh, Roberta Rudà, Edward R Scheffer Cliff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell LymphomaEdward R Scheffer Cliff, David A Russler-Germain, C Joseph Ross Daval, et al.
Ejhaem|September 2, 2022
Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressionsAjay Major, Edward R Scheffer Cliff, Daniel A Ermann, et al.
Eclinicalmedicine|July 21, 2025
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort studyAriadna Tibau, Edward R Scheffer Cliff, Alejandra Romano, et al.
Journal of the National Cancer Institute|July 21, 2025
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021Ariadna Tibau, Alejandra Romano, Ian T T Liu, et al.
JAMA Oncology|November 14, 2024
Advancing Global Pharmacoequity in OncologyParsa Erfani, Ruth L Okediji, Vivienne Mulema, et al.
Blood Advances|December 21, 2023
Utility of FDG-PET in predicting the histology of relapsed or refractory lymphomaShin Hnin Wai, Sze Ting Lee, Edward R Scheffer Cliff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2024
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma PatientsTobias Tix, Mohammad Alhomoud, Roni Shouval, et al.
Leukemia & Lymphoma|September 24, 2024
Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteriaSara Zhukovsky, Joshua White, Rajshekhar Chakraborty, et al.
Leukemia & Lymphoma|August 2, 2023
Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated diseaseThomas E Lew, Edward R Scheffer Cliff, Michael Dickinson, et al.
Pageof 4